公开(公告)号：US20230338410A1

公开(公告)日：2023-10-26

申请号：US18167984

申请日：2023-02-13

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

CPC classification number: A61K31/7115 ,  A61K9/0019 ,  A61K9/127 ,  C12N15/113 ,  C12N15/67 ,  C12N2310/141 ,  C12N2800/107 ,  C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20230086537A1

公开(公告)日：2023-03-23

申请号：US17608359

申请日：2020-05-07

Applicant: ModernaTX, Inc.

Inventor： Ruchi JAIN ,  Gilles BESIN ,  Elizaveta ANDRIANOVA

IPC: C12N15/88 ,  A61K31/7088

Abstract: The disclosure features mRNAs engineered with one or more microRNA binding sites targeted by a microRNA(s) that are differentially expressed in a target immune cell relative to a plurality of non-target immune cells. The disclosure also features methods of using the same, for example, for selectively degrading the mRNA in the target immune cell relative to the plurality of non-target immune cells.

公开(公告)号：US20230027864A1

公开(公告)日：2023-01-26

申请号：US17747618

申请日：2022-05-18

Applicant: ModernaTX, Inc.

Inventor： Gilles BESIN ,  Luis BRITO ,  Stephen G. HOGE ,  Edward HENNESSY ,  Mark CORNEBISE ,  Kerry BENENATO ,  Staci SABNIS ,  Michael W. DANNEMAN

IPC: A61K9/51 ,  A61P35/00 ,  A61K39/245 ,  C07K14/525 ,  C07K14/705

Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.

公开(公告)号：US20210260097A1

公开(公告)日：2021-08-26

申请号：US17036374

申请日：2020-09-29

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/00 ,  A61K9/127 ,  C12N15/113

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20190314291A1

公开(公告)日：2019-10-17

申请号：US16262758

申请日：2019-01-30

Applicant: ModernaTX, Inc.

Inventor： Gilles BESIN ,  Luis BRITO ,  Stephen G. HOGE ,  Edward HENNESSY ,  Mark CORNEBISE ,  Kerry BENENATO ,  Staci SABNIS ,  Michael W. DANNEMAN

IPC: A61K9/51 ,  C07K14/525 ,  A61P35/00 ,  C07K14/705 ,  A61K39/245

Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.

公开(公告)号：US20180256628A1

公开(公告)日：2018-09-13

申请号：US15761220

申请日：2016-10-05

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/127 ,  A61K9/00 ,  C12N15/113

CPC classification number: A61K31/7115 ,  A61K9/0019 ,  A61K9/127 ,  C12N15/113 ,  C12N15/67 ,  C12N2310/141 ,  C12N2800/107 ,  C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.